|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
CA3083779A1
(en)
|
2017-12-22 |
2019-06-27 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
CN112055717B
(zh)
|
2018-04-02 |
2024-04-26 |
新加坡国立大学 |
用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
EP3924467A1
(en)
*
|
2019-02-15 |
2021-12-22 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
AU2020271523A1
(en)
*
|
2019-04-11 |
2021-10-14 |
Fate Therapeutics, Inc. |
CD3 reconstitution in engineered iPSC and immune effector cells
|
|
WO2021009694A1
(en)
*
|
2019-07-17 |
2021-01-21 |
National University Of Singapore |
Functional binders synthesized and secreted by immune cells
|
|
BR112022000641A2
(pt)
*
|
2019-07-17 |
2022-03-29 |
Fate Therapeutics Inc |
Modificação genética de célula efetora imune e uso da mesma
|
|
KR20220058579A
(ko)
|
2019-09-05 |
2022-05-09 |
크리스퍼 테라퓨틱스 아게 |
보편적 공여자 세포
|
|
CA3149585A1
(en)
*
|
2019-09-25 |
2021-04-01 |
Bahram VALMEHR |
Multi-targeting effector cells and use thereof
|
|
BR112022006440A2
(pt)
*
|
2019-10-07 |
2022-07-05 |
Fate Therapeutics Inc |
Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
|
|
MX2022004107A
(es)
*
|
2019-10-09 |
2022-08-10 |
Bluerock Therapeutics Lp |
Celulas con expresion transgenica sostenida.
|
|
EP4045539A4
(en)
*
|
2019-10-17 |
2024-03-13 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
MX2022006725A
(es)
*
|
2019-12-06 |
2022-08-22 |
Fate Therapeutics Inc |
Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños.
|
|
EP3858999A1
(en)
*
|
2020-01-30 |
2021-08-04 |
Aelian Biotechnology GmbH |
Safe harbor loci
|
|
CN111269326A
(zh)
*
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
|
MX2022013182A
(es)
*
|
2020-04-24 |
2023-01-16 |
Merus Nv |
Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.
|
|
CN116018158A
(zh)
*
|
2020-04-30 |
2023-04-25 |
转化基因组学研究所 |
新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
|
|
KR20220166837A
(ko)
*
|
2020-06-11 |
2022-12-19 |
난징 바이오흐엥 바이오테크 씨오., 엘티디 |
Nk억제 분자를 발현하는 조작된 면역 세포 및 그 용도
|
|
AU2021292695A1
(en)
|
2020-06-19 |
2023-02-02 |
Fate Therapeutics, Inc. |
Combining iPSC-derived effector cell types for immunotherapy use
|
|
CN113528452B
(zh)
*
|
2020-07-06 |
2023-06-06 |
上海鑫湾生物科技有限公司 |
共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用
|
|
US20230248825A1
(en)
*
|
2020-07-24 |
2023-08-10 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
CN114276996A
(zh)
*
|
2020-09-28 |
2022-04-05 |
未来智人再生医学研究院(广州)有限公司 |
一种表达pd-1/pd-l1阻断物的多能干细胞衍生物及应用
|
|
WO2022072712A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Vor Biopharma Inc. |
Chimeric antigen receptor expression systems
|
|
IL301983A
(en)
*
|
2020-10-09 |
2023-06-01 |
Fate Therapeutics Inc |
Transgenic induced pluripotent stem cells and effector carrier cells of the immune system
|
|
WO2022094061A1
(en)
*
|
2020-10-28 |
2022-05-05 |
Sri International |
Genetically engineered antigen-specific natural killer cells for in situ synthesis of proteins
|
|
CN114426953A
(zh)
*
|
2020-10-29 |
2022-05-03 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-12的多能干细胞衍生物及应用
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
CN114525254A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达fgf-21的多能干细胞或其衍生物及应用
|
|
CN114525258A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达pcsk9阻断物的多能干细胞或其衍生物及应用
|
|
CN114457028A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38抗体的多能干细胞及其衍生物与应用
|
|
CN114457031A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达b7-h5阻断物的多能干细胞或其衍生物及应用
|
|
CN114457022A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
|
|
CN114457025A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达btla阻断物的多能干细胞或其衍生物及应用
|
|
CN114517184A
(zh)
*
|
2020-10-30 |
2022-05-20 |
未来智人再生医学研究院(广州)有限公司 |
一种表达adipsin的多能干细胞或其衍生物及应用
|
|
CN114525259B
(zh)
*
|
2020-11-03 |
2025-02-14 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
|
WO2022095902A1
(en)
*
|
2020-11-03 |
2022-05-12 |
Hangzhou Qihan Biotechnology Co., Ltd. |
Systems and methods for enhanced immunotherapies
|
|
CA3196549A1
(en)
*
|
2020-11-04 |
2022-05-12 |
Bahram Valamehr |
Engineered ipsc and immune effector cells for heterogenous tumor control
|
|
JP2023548467A
(ja)
*
|
2020-11-04 |
2023-11-17 |
フェイト セラピューティクス，インコーポレイティド |
操作されたｉＰＳＣ及び持続性免疫エフェクター細胞
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
AU2021392032A1
(en)
|
2020-12-03 |
2023-06-22 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
CN114645018A
(zh)
*
|
2020-12-18 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
CN114645020A
(zh)
*
|
2020-12-21 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向nr4a1抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657135A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Tim-3靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CA3203180A1
(en)
*
|
2020-12-23 |
2022-06-30 |
Robert Tighe |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20220193134A1
(en)
*
|
2020-12-23 |
2022-06-23 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
KR20230146007A
(ko)
|
2020-12-31 |
2023-10-18 |
크리스퍼 테라퓨틱스 아게 |
범용 공여자 세포
|
|
CA3204417A1
(en)
*
|
2021-01-29 |
2022-08-04 |
Allogene Therapeutics, Inc. |
Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
|
|
WO2022169870A1
(en)
*
|
2021-02-02 |
2022-08-11 |
Carisma Therapeutics Inc. |
Self-polarizing immune cells
|
|
CN117377756A
(zh)
*
|
2021-03-05 |
2024-01-09 |
菲克特生物科学股份有限公司 |
工程化免疫细胞疗法
|
|
MX2023011927A
(es)
*
|
2021-04-07 |
2023-10-23 |
Century Therapeutics Inc |
Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
|
|
AU2022283291A1
(en)
*
|
2021-05-27 |
2023-11-02 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
WO2022269393A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
|
WO2023006082A1
(zh)
*
|
2021-07-30 |
2023-02-02 |
启愈生物技术(上海)有限公司 |
抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
|
|
US20250127812A1
(en)
*
|
2021-08-10 |
2025-04-24 |
GentiBio. Inc. |
Compositions and methods for engineering stable tregs
|
|
CN114107378A
(zh)
*
|
2021-09-13 |
2022-03-01 |
钦元再生医学(珠海)有限公司 |
一种通用型car-t细胞的制备方法
|
|
IL312565A
(en)
*
|
2021-11-08 |
2024-07-01 |
Fate Therapeutics Inc |
Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
|
|
CN116103239A
(zh)
*
|
2021-11-11 |
2023-05-12 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
|
EP4445136A4
(en)
*
|
2021-12-06 |
2025-12-31 |
Wuxi Biologics Ireland Ltd |
3D BIOASSESSMENTS FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY MEASUREMENT
|
|
CN114414541A
(zh)
*
|
2021-12-17 |
2022-04-29 |
上海药明生物医药有限公司 |
一种应用3d细胞成像分析系统检测t细胞杀伤效力的方法
|
|
WO2023116929A1
(en)
*
|
2021-12-24 |
2023-06-29 |
Hemacell Therapeutics Inc. |
Method for producing human induced pluripotent stem cells through homologous recombination and integrase-mediated recombination
|
|
CN114317607B
(zh)
*
|
2021-12-31 |
2024-08-02 |
苏州桑尼赛尔生物医药有限公司 |
融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法
|
|
AU2023238456A1
(en)
*
|
2022-03-25 |
2024-10-17 |
Hk Inno.N Corporation |
Anti-hla-g chimeric antigen receptor, and use thereof
|
|
CA3247010A1
(en)
|
2022-04-08 |
2023-10-12 |
Ono Pharmaceutical Co., Ltd. |
CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
|
|
EP4504914A4
(en)
|
2022-04-08 |
2026-04-29 |
Fate Therapeutics Inc |
Cells having solid tumor targeting backbone and use thereof
|
|
CN116948012B
(zh)
*
|
2022-04-13 |
2024-07-26 |
星奕昂(上海)生物科技有限公司 |
增强细胞功能的cd16抗剪切突变体
|
|
CN114478806B
(zh)
*
|
2022-04-14 |
2022-07-01 |
呈诺再生医学科技(北京)有限公司 |
一种提升免疫细胞杀伤活性的嵌合受体及其应用
|
|
US20250354118A1
(en)
|
2022-06-09 |
2025-11-20 |
Umoja Biopharma, Inc. |
Compositions and methods for nk cell differentiation
|
|
EP4299734A1
(en)
*
|
2022-07-01 |
2024-01-03 |
ETH Zurich |
Cell line for discovering tcr antigens and uses thereof
|
|
CA3263301A1
(en)
|
2022-07-27 |
2024-02-01 |
Umoja Biopharma, Inc. |
Differentiation of stem cells in suspension culture
|
|
CN116042527B
(zh)
*
|
2022-09-07 |
2023-08-22 |
广州瑞臻再生医学科技有限公司 |
一种促进NK细胞分化的iPS细胞系及其构建方法与应用
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN116445414B
(zh)
*
|
2023-03-03 |
2025-07-08 |
广州瑞臻再生医学科技有限公司 |
基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用
|
|
CN116410336B
(zh)
*
|
2023-06-02 |
2023-09-22 |
云南赛元生物技术有限公司 |
一种嵌合抗原受体的编码核苷酸、car-nk细胞及其构建方法和应用
|
|
WO2025146467A1
(en)
|
2024-01-04 |
2025-07-10 |
Onk Therapeutics Limited |
Targeted il-15 construct delivery
|
|
WO2025158400A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Yale University |
Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
|
|
CN117946973B
(zh)
*
|
2024-03-26 |
2024-05-28 |
苏州艾凯利元生物科技有限公司 |
一种CAR-iNK细胞及其制备方法与应用
|